Amneal and others pay $1.5m to settle antitrust suit over Alzheimer’s drug

Amneal and three other generic makers have agreed to pay $1.54 million to settle a class-action lawsuit, which alleged the companies engaged in an unlawful scheme to maintain their monopoly over an Alzheimer’s drug.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Allergan pays $750m to resolve antitrust litigation

29 October 2019 Allergan has reached a $750 million deal to resolve antitrust litigation brought against its subsidiary Forest Laboratories over Alzheimer’s drug Namenda.

Americas

Generic drugmaker to pay $3m antitrust fine

5 December 2019 New Jersey-based generic drugmaker Rising Pharmaceuticals has admitted to conspiring to fix prices and allocate customers for a generic hypertension drug.

Americas

Judge gives initial approval to Actavis $20m antitrust deal

15 September 2020 A Massachusetts judge has provided her preliminary approval to a $19.9 million settlement in a class action antitrust suit brought against pharmaceutical company Actavis.

More on this story

Americas

Allergan pays $750m to resolve antitrust litigation

29 October 2019 Allergan has reached a $750 million deal to resolve antitrust litigation brought against its subsidiary Forest Laboratories over Alzheimer’s drug Namenda.

Americas

Generic drugmaker to pay $3m antitrust fine

5 December 2019 New Jersey-based generic drugmaker Rising Pharmaceuticals has admitted to conspiring to fix prices and allocate customers for a generic hypertension drug.

Americas

Judge gives initial approval to Actavis $20m antitrust deal

15 September 2020 A Massachusetts judge has provided her preliminary approval to a $19.9 million settlement in a class action antitrust suit brought against pharmaceutical company Actavis.

More on this story

Americas

Allergan pays $750m to resolve antitrust litigation

29 October 2019 Allergan has reached a $750 million deal to resolve antitrust litigation brought against its subsidiary Forest Laboratories over Alzheimer’s drug Namenda.

Americas

Generic drugmaker to pay $3m antitrust fine

5 December 2019 New Jersey-based generic drugmaker Rising Pharmaceuticals has admitted to conspiring to fix prices and allocate customers for a generic hypertension drug.

Americas

Judge gives initial approval to Actavis $20m antitrust deal

15 September 2020 A Massachusetts judge has provided her preliminary approval to a $19.9 million settlement in a class action antitrust suit brought against pharmaceutical company Actavis.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool

USPTO clarifies AI's role in patent eligibility

Amneal and others pay $1.5m to settle antitrust suit over Alzheimer’s drug

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features